World Class Bodybuilding & fitness

Go Back   World Class Bodybuilding & fitness > WorldClass RSS Feeds > RSS Bodybuilding Related Article Feeds > Peptides Feeds

Shoutbox
Loading...


Reply
 
LinkBack Thread Tools Display Modes
  #1  
Old 11-21-2009, 05:15 AM
basskiller's Avatar
Administrator



 
Join Date: Jan 2004
Location: Chasing the Naturals out of my gym
Posts: 49,516
Thanks: 430
Thanked 1,032 Times in 793 Posts
basskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond repute
rss Human Growth Hormone - Effectiveness of the Combined Recombinant Human Growth Hormone

J Clin Endocrinol Metab. 2009 Nov 19;
Scalco RC, Melo SS, Pugliese-Pires PN, Funari MF, Nishi MY, Arnhold IJ, Mendonca BB, Jorge AA
Context: Isolated heterozygous SHOX defects are the most frequent monogenic cause of short stature, and combined therapy with recombinant human GH (rhGH) and GnRH analog (GnRHa) in pubertal patients has been suggested, but there are no data on final height. Objective: The aim of the study was to analyze adult height after rhGH and GnRHa therapy in patients with SHOX haploinsufficiency. Patients: Ten peripubertal patients with isolated SHOX defects participated in the study. Intervention: Five patients were followed without treatment, and five were treated with rhGH (50 mug/kg/d) and depot leuprolide acetate (3.75 mg/month). Main Outcome Measures: Adult height SD score (SDS) was measured. Results: All patients followed without treatment had marked downward growth shift during puberty (height SDS, -1.2 +/- 0.7 at 11.4 +/- 1.4 yr; adult height SDS, -2.5 +/- 0.5). Conversely, four of five patients treated with rhGH for 2 to 4.9 yr associated to GnRHa for 1.4 to 5.8 yr improved their height SDS from -2.3 +/- 1.3 at 11.8 +/- 2.1 yr to a final height SDS of -1.7 +/- 1.6. The difference between the mean height SDS at the first evaluation and final height SDS was statistically significant in nontreated vs. treated patients (mean height SDS change, -1.2 +/- 0.4 vs. 0.6 +/- 0.4, respectively; P
__________________

W C B B Sponsors

TruePeptides <-- Peptide needs
Tan Research <-- Tanning needs
ResearchStop <-- Research Chemical needs
ProWristStraps <-- Lifting Equipment needs
TNB Medical Supplies <-- Medical Supply needs

By supporting our sponsors, you are supporting our WCBB Community!
Reply With Quote
Sponsored Links
Reply


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On



All times are GMT -4. The time now is 03:03 AM.


Powered by vBulletin
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.
Content Relevant URLs by vBSEO 3.2.0